Advertisement
Canada markets open in 4 hours 39 minutes

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7310
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    79.52
    +0.26 (+0.33%)
     

  • Bitcoin CAD

    86,079.15
    +2,093.91 (+2.49%)
     

  • CMC Crypto 200

    1,304.99
    -53.02 (-3.90%)
     

  • GOLD FUTURES

    2,374.70
    +34.40 (+1.47%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • NASDAQ futures

    18,269.75
    +55.25 (+0.30%)
     

  • VOLATILITY

    12.78
    +0.09 (+0.71%)
     

  • FTSE

    8,429.55
    +48.20 (+0.58%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6776
    -0.0002 (-0.03%)
     

DuPont Receives Exclusive License from Vilnius University - Analyst Blog

Zacks Equity Research
Updated

DuPont DD declared that it has signed a technology license and research collaboration agreement with Vilnius University for the advancement of the technical and commercial utility of guided Cas9 genome editing technology. Financial terms of the agreement remain undisclosed.

Per the agreement, DuPont will get the license to use Vilnius University intellectual property for all commercial purposes, including agricultural uses. Moreover, both the companies will collaborate on a multi-year research project to further the development of this technology.

A team of scientists from the Vilnius University Institute of Biotechnology was one of the first groups to find out that the Cas9 protein could be reused in plants to make them drought- and disease-resistant, protect plant health and lead to higher plant yields.

According to Neal Gutterson, Vice President of Agricultural Biotechnology for DuPont Pioneer, the guided Cas9 technology is a remarkable discovery in biology. Its advanced properties will help scientists develop sustainable solutions which will provide farmers with increased accuracy in plant breeding. It will further position DuPont as a pioneer in the adoption of this promising new technology in agriculture.

Guided Cas9 genome editing technology is one of many CRISPR-derived tools. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a feature that is naturally present in bacteria. DuPont’s portfolio comprises more than 60 patents and patent applications associated with the use of CRISPR.

DuPont currently carries a Zacks Rank #3 (Hold).

Better-ranked chemical stocks include LyondellBasell Industries N.V. LYB, Stepan Company SCL and Trecora Resources TREC, all sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DU PONT (EI) DE (DD): Free Stock Analysis Report
 
LYONDELLBASEL-A (LYB): Free Stock Analysis Report
 
TRECORA RESRCS (TREC): Free Stock Analysis Report
 
STEPAN CO (SCL): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research